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Abstract
Induced cell fusion has enabled several important discoveries, including the phenomenon of nuclear reprogramming and
may yet be applied as a novel therapy for degenerative diseases. However, existing fusogens lack the efficiency required to
enable investigation of the epigenetic modifications underlying nuclear reprogramming and the specificity required for
clinical application. Here we present a chimeric measles hemagglutinin, Ha7, which specifically and efficiently mediates the
fusion of diverse cell types with skeletal muscle both in vitro and in vivo. When compared directly to polyethylene glycol,
Ha7 consistently generated a substantial increase in heterokaryon yield and exhibited insignificant levels of toxicity.
Moreover, this increased fusion efficiency enabled detection of chromatin modifications associated with nuclear
reprogramming following Ha7-mediated fusion of human fibroblasts and mouse myotubes. Finally, Ha7 was also capable
of increasing the contribution of transplanted fibroblasts to skeletal muscle repair in vivo, suggesting that this strategy
could be used for therapeutic gene delivery.
Citation: Long MA, Rossi FMV (2011) Targeted Cell Fusion Facilitates Stable Heterokaryon Generation In Vitro and In Vivo. PLoS ONE 6(10): e26381. doi:10.1371/
journal.pone.0026381
Editor: Marc Tjwa, University of Frankfurt - University Hospital Frankfurt, Germany
Received May 11, 2011; Accepted September 26, 2011; Published October 24, 2011
Copyright:  2011 Long, Rossi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a research grant from Jesse’s Journey (www.jessesjourney.com). MAL was supported by training grants from the Stem
Cell Network (www.stemcellnetwork.ca) and Muscular Dystrophy Canada (www.muscle.ca). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fabio@brc.ubc.ca
Introduction
Techniques for inducing the fusion of cells in vitro have been
essential for research in a number of fields including the study of
nuclear reprogramming [1], the production of monoclonal
antibodies [2] and the generation of dendritic cell hybrids for
cancer immunotherapy [3]. However, advances in these and other
areas are currently encumbered by the limitations of traditional
fusogenic agents. The most commonly utilized techniques for
inducing cell fusion in vitro, namely polyethylene glycol (PEG) [4]
and electrofusion [5] were first described roughly thirty years ago
and although incremental refinements have gradually increased
their efficacy, each of these methods remain notoriously inefficient.
As a result of mechanisms that rely on random aggregation and
membrane damage in order to achieve cell fusion, PEG and
electrofusion protocols generally produce heterokaryons with low
efficiency and high toxicity. Methods that employ micromanipu-
lation [6], affinity crosslinking [7] or microfluidic devices [8] to
properly pair two cell types are capable of increasing the efficiency
of fusion. However, these systems continue to rely on the induction
of membrane damage to initiate cell fusion.
In vivo, the ability of bone marrow derived cells and transplanted
fibroblasts to contribute to the repair of several organs is largely
thought to be due to the fusion of these cells with damaged tissues
[9,10]. This discovery has raised the prospect that cell fusion may
represent a viable therapeutic strategy for several genetic and
degenerative diseases. However, the inefficiency with which this
phenomenon occurs has also precluded its therapeutic utility.
Attempts to increase the efficiency of this process, including
injection of snake venom toxins, appear to function by simply
damaging tissue which in turn recruits inflammatory cells to the
site of injury where they infrequently fuse to regenerating tissue
[11]. Clearly, for such approaches to be clinically applicable, an
increase in the specificity and efficiency of cell fusion is required.
Members of the Paramyxoviridae family of viruses, including
measles and Sendai virus have long been known to induce cell
fusion in vivo and in vitro [12,13]. In the case of measles virus,
infection is initiated via recognition of human CD46 or CD150 on
the surface of cells by the viral hemagglutinin (H) protein [14,15].
This interaction is believed to induce a conformational change in
the associated viral fusion (F) protein, exposing a hydrophobic
peptide, which inserts into the target plasma membrane and
mediates fusion of the virus with the cell [16]. Subsequent display
of measles H and F on the surface of infected cells then initiates
fusion between neighboring cells, ultimately resulting in large
multinucleated syncytia. Recently, a number of groups have
altered the tropism of measles virus via addition of peptides [17],
growth factors [18], single chain antibodies (scFv) [19] or cytokines
[20] to the carboxyl-terminus of the hemagglutinin protein. The
primary application of this technology has been the creation of
oncolytic measles viruses, which are capable of specifically
recognizing, infecting and killing tumor cells. However, consider-
ing that the H/F glycoprotein complex is capable of mediating cell
fusion in the absence of viral infection [21], we hypothesized that
chimeric measles hemagglutinin proteins could also be used to
increase the efficiency of stable heterokaryon formation in vitro as
well as for fusion-based cell therapy in vivo.
Here we present a targeted cell fusion approach based on a
chimeric measles virus hemagglutinin glycoprotein, which is
capable of generating stable heterokaryons with high efficiency
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Ha7, was produced by addition of a scFv that recognizes the
muscle specific integrin, alpha7, to the carboxyl-terminus of a
mutant hemagglutinin. Co-transfection of plasmids encoding Ha7
and measles F, induced fusion of all cell types tested with cultured
skeletal muscle fibers. Moreover, the efficiency of Ha7-mediated
fusion was clearly superior to PEG-mediated fusion and
demonstrated insignificant levels of toxicity. Following Ha7-
mediated fusion of human fibroblasts and mouse myotubes,
transcription of the myogenic regulatory factors, MyoD and
myogenin, as well as expression of neural cell adhesion molecule
(NCAM) was activated in human nuclei. The level of human
MyoD and myogenin mRNA detected following Ha7-mediated
fusion was much greater than the level detected following PEG-
mediated fusion, exceeding a ten-fold increase at most time points.
Additionally, the increased efficiency of Ha7-mediated fusion
enabled the detection of histone H3K9/K14 acetylation at the
human MyoD promoter, demonstrating the utility of this method
for the elucidation of epigenetic events underlying the process of
reprogramming. Finally, transplanted fibroblasts expressing Ha7
specifically and efficiently fused with skeletal muscle fibers in vivo,
suggesting that targeted cell fusion may represent a novel strategy
for regenerative medicine.
Results
Design, construction and characterization of Ha7
In order to generate a muscle-specific fusion reagent, we first
constructed an anti-alpha7-integrin scFv from the well-character-
ized CA5.5 monoclonal antibody, which has been employed
extensively in the purification and characterization of myoblasts
[22]. As seen in Figure 1A–D, the scFv retains the specificity of the
parental monoclonal antibody, demonstrated by its ability to stain
C2C12 myoblasts but not NIH/3T3 fibroblasts. The anti-alpha7-
integrin scFv was subsequently added to the carboxyl terminus of a
mutated measles hemagglutinin, H481A,533A, which lacks the ability
to bind either measles receptor [23] in order to create Ha7
(Figure 1E). We then tested the ability of cells exogenously
expressing our chimeric hemagglutinin to fuse with differentiated
skeletal myotubes. In order to accomplish this, 293T cells were
transiently co-transfected with plasmids encoding Ha7, F and
GFP. The following day, these cells were mixed with cultures of
differentiated C2C12 myotubes and twenty-four hours after
mixing, the percentage of GFP-positive myotubes was determined.
As seen in Figure 1F,G transfection of as little as 5 ng of each
plasmid was sufficient to induce fusion of 293T cells with the
majority (90% +/2 3%) of myotubes in the culture. Importantly,
very low numbers (1.0% +/2 2%) of GFP-positive myotubes were
observed in the same assay when H481A,533A was used in place of
Ha7 and were completely absent when Ha7 or F were omitted
from the transfection (Figure 1F).
Verification of heterokaryon status following
Ha7-mediated fusion
In order to eliminate the possibility that the multinucleated,
GFP-positive cells observed in co-cultures were exclusively derived
from the homotypic fusion of transfected cells, we differentially
labeled two populations of 293T cells via co-transfection of either
GFP or mCherry in addition to Ha7 and F and subsequently co-
cultured these cells in myogenic differentiation medium. This
treatment did not result in the formation of syncytia (Figure 2A),
suggesting that transfected 293T cells are unable to autonomously
initiate the fusion process and demonstrating the inability of Ha7
to facilitate fusion between cells that do not express alpha7
integrin. In co-cultures of transfected 293T and C2C12 cells
however, multinucleated, GFP-positive cells were found to express
sarcomeric myosin heavy chain (Figure 2B–D), confirming the
presence of proteins derived from both cell types within these
syncytia. Furthermore, we identified the presence of both human
and murine nuclei within these syncytia by differential DAPI
staining (Figure 2E) as well as by fluorescent-in situ-hybridization
(FISH) staining of human and murine satellite repeat DNA
(Figure 2F). In the FISH assay, double-positive nuclei were never
observed, indicating that following Ha7-mediated fusion of 293T
cells with differentiated C2C12 myotubes, distinct nuclei are
maintained within syncytia, thereby confirming the identity of
these cells as true heterokaryons.
Comparison of Ha7 and PEG induced fusion
PEG remains the most widely used fusogenic agent for the
production of heterokaryons. Therefore, we sought to compare the
efficiency of Ha7-mediated fusion with that of a standard PEG-
mediated fusion protocol. In this case, 293T cells were either co-
transfected with plasmids encoding Ha7, F and GFP or transfected
with a plasmid encoding GFP alone. The following day, equal
numbers of 293THa7/F/GFP or 293TGFP cells were mixed with
cultures of differentiating C2C12 cells and wells containing
293TGFP were treated with PEG to induce fusion. The number
of GFP-positive myotubes as well as the total number of myotubes
per low-power field was determined daily thereafter for each
condition. As expected, cells expressing Ha7 fused with the
majority of myotubes in the culture (Figure 3A–C and Table S1).
In cultures treated with PEG however, GFP-positive myotubes
were much less frequent, with a maximum of 13% +/2 5%
observed at twenty-four hours post-fusion (Figure 3A–C and Table
S1). This finding is unlikely to be due to improper use of PEG, as
previous studies employing this method have reported similar
fusion efficiencies [24]. At all timepoints, the total number of
myotubes surviving in the Ha7 treatment group was nearly twice
as great as the number surviving PEG treatment. In fact, the total
number of myotubes present following Ha7-mediated fusion was
not significantly different from controls lacking any fusogen,
demonstrating the lack of toxicity of this method. Ultimately, the
combination of increased efficiency and reduced toxicity of Ha7-
mediated fusion resulted in a 12 to 17-fold increase heterokaryon
yield over the standard PEG-mediated fusion protocol (Table S2).
A decrease in the total number of myotubes was observed on day
three post-fusion as differentiated muscle cells began to contract
and detach from the dish. However, this phenomenon uniformly
affected the total number of myotubes across all treatment groups
and did not preferentially affect GFP-positive myotubes within any
group, suggesting that this is a normal behavior of myotubes in
culture rather than an effect of fusion-inducing treatments.
Nuclear reprogramming following Ha7-mediated fusion
A number of significant discoveries in the field of nuclear
reprogramming have been made via fusion of various cell types
with differentiating myotubes in vitro [1,25–28]. However, the low
efficiency of existing fusogenic agents has generally encumbered
these experiments, slowing advances in our understanding of this
phenomenon. Therefore, in order to demonstrate that the
increased yield of heterokaryons generated via Ha7-mediated
fusion is capable of overcoming these limitations, we analyzed
induction of the human myogenic regulatory factor, MyoD, in
heterokaryons comprised of MRC-5 human lung fibroblasts and
differentiating C2C12 myotubes. As seen in Figure 4A, isolated
MRC-5 cells do not express this transcription factor. However,
following Ha7-mediated fusion, expression of human MyoD was
Heterokaryon Generation via Targeted Cell Fusion
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fusion and reaching a peak forty-eight hours later (Figure 4B).
Transcription of human MyoD was then downregulated over time,
resembling its kinetics of expression during the differentiation of
normal myogenic cells [29]. In contrast, following PEG-mediated
fusion of MRC-5 cells and differentiating C2C12 myotubes,
expression of human MyoD was not detected until forty-eight
hours after fusion and remained at low levels throughout the time
course (Figure 4C). When compared directly, these data reveal that
the level of human MyoD expression detected at daily intervals
following Ha7-mediated fusion was up to 94-fold higher than the
level observed following PEG-mediated fusion (Table S3).
In order to confirm that nuclear reprogramming following Ha7-
mediated fusion is not a transient phenomenon, restricted to the
expression of human MyoD, we also analyzed induction of a
second myogenic regulatory factor, myogenin, in heterokaryons
generated via Ha7 and PEG mediated fusion. As seen in
Figure 4D, this transcription factor is rapidly induced and stably
transcribed in heterokaryons generated via either protocol.
However, the level of human myogenin transcript detected at
daily intervals following Ha7-mediated fusion was up to 31-fold
higher than the level observed following PEG-mediated fusion
(Table S3). Finally, as further evidence of the extent and stability of
nuclear reprogramming following Ha7-mediated fusion, we also
detected expression of human NCAM in 85% +/2 9% of
heterokaryons on day eight post-fusion (Figure S1).
Ha7-mediated fusion also enabled us to investigate the
dynamics of histone H3K9/K14 acetylation at the human MyoD
promoter during the reprogramming process. Although this
modification is well known to be associated with transcriptional
activation, its induction has not previously been described at
individual loci during the process of reprogramming due to the
insufficient yield of heterokaryons generated by PEG mediated
fusion [30]. As seen in Figure 4E, histone H3K9/K14 acetylation
of the human MyoD promoter is not detected in unfused MRC-5
cells, consistent with the fact that MyoD is not expressed in these
cells. However, following Ha7-mediated fusion, histone H3K9/
K14 acetylation of the human MyoD promoter is observed within
twenty-four hours (Figure 4F). Although acetylation appears to
peak at four days post-fusion, there is no statistically significant
difference between any time point past day one, suggesting that
histone H3K9/K14 acetylation of the human MyoD promoter
reaches stable levels rapidly following fusion.
Ha7-mediated fusion in vivo
Finally, to evaluate the potential utility of targeted cell fusion for
regenerative medicine, we investigated the ability of Ha7t o
increase the efficiency of fusion between non-myogenic cells and
Figure 1. Design, construction and characterization of Ha7. (A–D) Evaluation of the anti-alpha7 integrin scFv by flow cytometry. The scFv (A,
solid line) retains the ability of the parental monoclonal antibody (C, solid line) to stain C2C12 myoblasts, whereas neither antibody stains NIH/3T3
fibroblasts (B and D, solid line). In all plots, the staining level of cells incubated with secondary antibody alone is shown in dotted lines. (E) Schematic
representation of Ha7, approximating the locations each blade (b1–b6) in the b-propeller fold as well as the location of mutations that abrogate
CD46 binding (Y481A) and CD150 binding (R533A). The anti-alpha7 integrin scFv is displayed as a carboxy-terminal extension of the type II
transmembrane glycoprotein. Standard one-letter abbreviations are used to denote amino acid residues. N: Amino-terminal cytoplasmic tail. TM:
Transmembrane domain. (F)H a7 mediates fusion of transfected 293T cells and differentiated C2C12 myotubes with an efficiency that is proportional
to the amount of transfected plasmid and is dependent on the presence of the anti-alpha7 integrin scFv and the measles F protein. Data are shown
as mean 6 s.d. of three independent fusion experiments. (G) Morphology of myotubes following fusion. Scale bar, 100 mm.
doi:10.1371/journal.pone.0026381.g001
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embryonic fibroblasts (MEF) were infected with the lentiviral
vectors, LV-HIG and LV-FIY, which encode Ha7-IRES-GFP
and F-IRES-YFP respectively, and cells were subsequently
purified by flow cytometry (Figure 5A,B). Doubly infected
MEFHa7/F as well as singly infected MEFHa7 control cells were
then transplanted into the tibialis anterior muscle of C57BL/6
recipient mice. One week after transplantation, mice were
sacrificed and hind limbs were examined for the presence of
GFP-positive muscle fibers. As seen in Figure 5C,D, a large
number of GFP-positive fibers exhibiting normal morphology and
surrounded by basal lamina were observed in all recipients (n=3)
of MEFHa7/F cells.
Considering the fact that various forms of muscle damage are
known to augment the contribution of transplanted cells to
myofiber regeneration, we also transplanted MEFHa7/F and
control MEFHa7 cells via intramuscular co-injection with the
myotoxic phospholipase, notexin [11,31,32]. As seen in Figure 5C,
the number of GFP-positive fibers observed following co-
administration of notexin was roughly 3.5-fold greater than the
number observed in undamaged recipients. Although the GFP-
positive fibers observed in notexin treated recipients were smaller
than those observed in undamaged recipients (Figure 5D,E) this
phenomenon is a common hallmark of regenerating muscle [33].
Importantly, among all recipients (n=6) of MEFHa7 control
cells, only a single GFP-positive fiber was detected (Figure 5C,F).
Furthermore, no GFP-positive cells were observed in the spleen,
lung or liver following transplantation of MEFHa7/F into either
damaged or undamaged recipients of (n=6) (Figure S2).
Discussion
We have created a cell fusion reagent, Ha7, which overcomes
the low efficiency, high toxicity and lack of specificity exhibited by
existing chemical and physical fusogens. As opposed to PEG and
electrofusion, our system is based on a specific ligand-receptor
interaction, which simultaneously promotes the proper pairing and
efficient fusion of cells. This feature maximizes the generation of
heterokaryons and virtually eliminates the non-productive forma-
tion of homokaryons. In vitro, cells expressing Ha7 routinely fused
with over 90% of cultured myotubes and consistently yielded 12 to
17-fold more heterokaryons than a standard PEG-mediated
protocol. A comparable increase in fusion efficiency has recently
been described utilizing a microfluidic device to control cell
pairing [8]. While this represents a significant improvement over
existing techniques, the microfluidic device is limited to the
manipulation of a maximum of six thousand cell pairs per run.
Our method on the other hand, has no inherent limitations of
scale and is therefore capable of producing far more heterokaryons
per experiment.
The ability of Ha7 to increase fusion efficiency was not gained
at the expense of cell viability. At all time points analyzed, the total
number of myotubes present following Ha7-mediated fusion was
not significantly different from controls lacking any fusogen.
Moreover, heterokaryons generated via Ha7 treatment exhibited
normal healthy morphology, characteristic of differentiated
C2C12 myotubes. In contrast, PEG-mediated fusion resulted in
the death of roughly half of the myotubes in culture. This
difference is likely due to the fact that unlike PEG, the measles
fusion glycoprotein complex is capable of initiating and stabilizing
the fusion process without relying on the induction of membrane
damage.
In heterokaryons generated via Ha7-mediated fusion of human
fibroblasts and mouse myotubes, transcription of the myogenic
regulatory factors, MyoD and myogenin, was activated in human
nuclei. The level of human MyoD and myogenin transcripts
detected following Ha7-mediated fusion was much greater than
the level detected following PEG-mediated fusion, suggesting that
this method may exhibit an increased sensitivity in general. While
it remains possible that the expression of Ha7 and F may alter
gene expression in heterokaryons, it is unlikely that this effect will
be greater than the perturbations caused by the toxic effects of
PEG. In fact, the use of a cell line such as MRC-5 Ha7/F, may
provide a standardized reagent for studies of nuclear reprogram-
ming and reduce inter-experimental variation caused by variable
batches or usage of PEG.
Chromatin modifications are well-known to enhance or repress
transcription and are likely to play a crucial role in establishing the
gene expression networks required for nuclear reprogramming
[34]. However, dynamic changes in chromatin modifications
Figure 2. Verification of heterokaryon status following Ha7-
mediated fusion. (A) Two populations of 293T cells labeled with
either GFP or mCherry and co-transfected with Ha7 and F do not fuse
with one another. (B–D) Following co-culture of transfected human
293T cells with differentiated mouse C2C12 myotubes, elongated GFP-
positive cells (B) express sarcomeric myosin heavy-chain (C) and
contain multiple nuclei (D, merged). (E) Differential DAPI staining
demonstrates the presence of both human and mouse nuclei within
heterokaryons. Mouse nuclei contain dense chromocenters (arrow)
while human nuclei stain diffusely and exhibit dark nucleoli (arrow-
head). (F) Fluorescent in situ hybridization of human a-satellite DNA
(red) and mouse c-satellite DNA (green) further confirms the presence
of both human and mouse nuclei within heterokaryons. Scale bars,
25 mm( A–D), 20 mm( E), 10 mm( F).
doi:10.1371/journal.pone.0026381.g002
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of GFP-positive myotubes (green bars) was determined by visual inspection of randomly selected, low power (5x) fields at 1 day (A), 2 days (B) and 3
days (C) post-fusion. The number of GFP-positive myotubes observed following Ha7-mediated fusion was significantly higher on all days than the
number observed following PEG-mediated fusion (green asterisks). The total number of myotubes surviving PEG treatment was significantly lower
than the total number observed in co-cultures lacking any fusogen (black asterisks). ***: p,0.001 (unpaired t-test). Data are shown as mean 6 s.d. of
three independent fusion experiments.
doi:10.1371/journal.pone.0026381.g003
Figure 4. Nuclear reprogramming following Ha7 or PEG-mediated fusion. (A) Endpoint RT-PCR reactions demonstrating specificity of the
primers used to amplify the human MyoD and myogenin transcripts. (B–C) Quantitative RT-PCR analysis reveals robust transcription of human MyoD
following Ha7-mediated fusion (B) of MRC-5 cells and differentiating C2C12 myotubes, whereas the level of MyoD transcript observed following PEG-
mediated fusion (C) is weak by comparison. (D) Likewise, the level of human myogenin transcript detected following Ha7-mediated fusion (black
bars) was greater than the level detected following PEG-mediated fusion (white bars) at each timepoint. All quantitative RT-PCR values were
normalized to b-actin transcript levels and subsequently to the mean expression level of Ha7-containing cultures on Day 1. (E) Endpoint PCR
reactions demonstrating specificity of the primers used to amplify a segment of the human MyoD promoter (lanes 1 and 2), normal rabbit IgG
chromatin immunoprecipitation (CHIP) control performed 8 days post-fusion (lane 3) and an aH3K9/K14 CHIP control performed on MRC-5 cells prior
to fusion (lane 4). (F) Chromatin immunoprecipitation reveals early and stable induction of histone H3K9/K14 acetylation at the human MyoD
promoter following Ha7-mediated fusion of MRC-5 cells and differentiating C2C12 myotubes. *: p,0.05 (unpaired t-test). All data are shown as mean
6 s.d. of three independent fusion experiments.
doi:10.1371/journal.pone.0026381.g004
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undescribed due to the paucity of cells generated by traditional
heterokaryon or transcription factor-based reprogramming meth-
ods. Here, we have exploited the greatly enhanced efficiency of
Ha7-mediated fusion to demonstrate that acetylation of histone
H3K9/K14 at the human MyoD promoter is rapidly induced
following fusion. Moreover, once established, this modification
remains stable despite the fact that expression of the MyoD gene is
only transiently upregulated, suggesting that other epigenetic
modifications may play a more important role in fine-tuning MyoD
expression following fusion. Overall, these results demonstrate that
the yield of heterokaryons generated by Ha7-mediated fusion is
sufficienttoenableidentification ofspecificchromatinmodifications
at loci of interest. Therefore, we anticipate that this technology will
facilitate the systematic identification of the factors and mechanisms
involved in the process of nuclear reprogramming.
Skeletal muscle is naturally repaired by satellite cells, which
proliferate and fuse to multinucleated myofibers [35]. However, in
several human skeletal myopathies, ongoing cycles of fiber
degeneration progressively deplete satellite cell numbers, impairing
the ability of myofibers to regenerate by incorporation of new nuclei
[36]. Unfortunately, satellite cells cannot be efficiently replaced by
transplantation [37]. Therefore, we utilized Ha7-mediated fusion to
create a novel method of delivering exogenous nuclei to myofibers.
In these proof of principle experiments, transplanted MEF Ha7/F
cells fused efficiently with recipient muscle fibers. The expression of
donorderivedGFPinthesemusclefibersdemonstratesthe potential
utility of Ha7-mediated fusion for the delivery of therapeutic
transgenes to skeletal muscle. Although we have examined this
reagent in the context of cell transplantation, Ha7-mediated
targeting of non-cellular delivery vehicles may also be possible
[38]. In addition, our results demonstrate that Ha7 is capable of
enhancing fusion of fibroblasts and skeletal muscle fibers in an
immunocompetent host. In agreement, Iankov et al, have
demonstrated that cells infected with measles virus are capable of
undergoing fusion in vivo even in the presence of pre-existing
humoral immunity [39]. Therefore we further anticipate that Ha7-
mediated fusion may facilitate the development of novel cell and
gene therapies for skeletal myopathies.
While the syncytial nature of myofibers may render skeletal
muscle innately amenable to a cell fusion based therapy, a small
number of other therapeutically interesting cell types including
cardiomyocytes and hepatocytes also naturally exist in multinu-
cleated states [40,41]. Furthermore, these cell types as well as
others including Purkinje neurons and renal proximal tubule
epithelial cells are known to tolerate fusion and exist as
heterokaryons following bone marrow transplantation [9,42].
However, as in the case of skeletal muscle, these fusion events
Figure 5. Ha7-mediated fusion in vivo. (A,B) Mouse embryonic fibroblasts infected with lentiviruses encoding Ha7-IRES-GFP and F-IRES-YFP (A)
or Ha7-IRES-GFP alone (B) were purified by flow cytometry and transplanted intramuscularly into wild-type recipients. (C) Cells expressing Ha7 and F
(MEFHa7/F) efficiently fused with host myofibers and this process was greatly augmented by co-injection of notexin. Conversely, cells expressing Ha7
alone (MEFHa7) did not fuse efficiently with host myofibers regardless of the presence or absence of notexin. Data are shown as mean 6 s.d.
**: p,0.01 (unpaired t-test). (D–F) Representative images demonstrating GFP-positive fibers (green) surrounded by a laminin sheath (red) in an
undamaged recipient of MEFHa7/F cells (D), a notexin-damaged recipient of MEFHa7/F cells (E) and a notexin-damaged recipient of MEFHa7 cells (F).
Scale bar, 100 mm.
doi:10.1371/journal.pone.0026381.g005
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in rare cases where heterokaryons exhibit a growth advantage over
resident cells [42,43]. Therefore, in order to treat the vast majority
of pathologies in which positive selection does not occur, the
efficiency of the fusion process must be increased. Clearly cell
surface markers of suitable specificity must be validated for each
cell type. However, if such markers can be identified, targeted cell
fusion may represent a novel therapeutic approach to a number of
degenerative diseases.
Materials and Methods
Ethics Statement
All experiments and procedures were approved by the
Committee on Animal Care (Protocol #A09-0364) at the
University of British Columbia, in accordance with the require-
ments of the Canadian Council on Animal Care (CCAC).
Construction of Ha7
RNA was prepared from the CA5.5 hybridoma (RNeasy,
Qiagen) and cDNA was produced utilizing Superscript II
(Invitrogen) and an oligo-dT primer. The variable region of the
immunoglobulin heavy chain was then amplified utilizing the
primers CA5.5H-F: 59-AAAAGATCTGGCCCAGCCGGCC-
CAGGTGCAGCTGAAGGAGTC-39and CA5.5H-R: 59-GACGG
TGACCATGACTCCTTGG-39. The variable region of the
immunoglobulin light chain was amplified utilizing the primers
CA5.5L-F: 59-AAAGAGCTCGCTGACCCAGTCTCCTGCTT
TG-39 and CA5.5L-R: 59-AAACTCGAGCGGCCGCCCGTTT
CAATTCCAGCTTGGTGC-39. A complete scFv was then
assembled by cloning the heavy chain fragment upstream and
the light chain fragment downstream of a glycine-serine (G4S1)3
linker contained in pASK85-9E10 utilizing BglII, BstEII and SacI,
XhoI sites respectively, thereby creating pCA5.5scFv.
The CA5.5scFv was subsequently fused to a human light chain
constant region by subcloning into pLC-huCk with BglII and
NotI. This plasmid, pCA5.5scFv- huCk, was transiently transfect-
ed into 293T cells via standard calcium phosphate precipitation
and forty-eight hours later, neat supernatant containing the
CA5.5scFv-huCk fusion protein was utilized to stain C2C12
myoblasts and NIH/3T3 fibroblasts in parallel with a 0.5 mg/mL
dilution of the CA5.5 monoclonal antibody. The goat anti-human-
kappa-PE (Southern Biotech) and goat anti-rat-PE (Southern
Biotech) secondary antibodies were used to detect CA5.5scFv-
huCk and CA5.5 staining respectively. All flow cytometry data
was collected with a Becton-Dickinson FACSCalibur and analyzed
with FlowJo software. Following confirmation of specificity, the
CA5.5scFv was fused to the carboxyl-terminus of a mutant measles
hemagglutinin contained in pTNH6-HAA using SfiI and NotI,
thereby creating pHa7.
In vitro fusion assays
293T and C2C12 cells were maintained in DMEM (Gibco)
supplemented with 10% and 20% fetal bovine serum (Gibco)
respectively. To induce differentiation, C2C12 cells were plated in
DMEM supplemented with 2% horse serum (Invitrogen) on
collagen-coated dishes (Sigma, Becton Dickinson) at a density of
4610
4 cells/cm
2. Twenty-four hours later, cytosine b-D-arabino-
furanoside (Ara-C) (Sigma) was added to a concentration of
1610
25 M in order to eliminate proliferating myoblasts. 293T
cells were transfected with calcium phosphate twenty-four hours
prior to co-culture and were plated onto C2C12 cells at a density
of 4610
4 cells/cm
2. Co-cultures were initiated following two or
five days of C2C12 differentiation and are referred to as
differentiating or differentiated cultures respectively.
PEG-mediated fusion of cells was carried out as described
previously [27]. Briefly, 293T cells were mixed with differentiating
C2C12 myoblasts and allowed to settle and adhere for four to six
hours. Medium was then completely aspirated and replaced with
prewarmed 50% PEG 1500 (Roche) for sixty seconds. PEG was
then removed and cells were washed three times in prewarmed
DMEM. Cultures were subsequently maintained in DMEM
supplemented with 2% horse serum, 1610
25 M Ara-C and
1610
25 M ouabbain (Sigma) to eliminate unfused human cells.
Fusion efficiency was quantified at selected intervals by enumer-
ating the total number of myotubes as well as the number of GFP-
positive myotubes present in at least three randomly selected low
power (5x) fields.
Immunofluorescence and FISH
To detect myosin-heavy chain expression, heterokaryons were
first fixed in 4% paraformaldehyde (PFA) for five minutes at room
temperature, washed in PBS and permeabilized in 0.5% Triton X-
100 for five minutes at room temperature. Cells were then stained
with mouse anti-myosin-heavy chain (Developmental Studies
Hybridoma Bank) overnight at 4uC, followed by a one hour
incubation with goat anti-mouse Alexa 568 (Molecular Probes) at
room temperature. Nuclei were counterstained with 49,6-diami-
dino-2-phenylindole (DAPI) (1 mg/mL). To detect NCAM expres-
sion, live cells were incubated with a 1:25 dilution of 5.1H11
hybridoma supernatant (Developmental Studies Hybridoma Bank)
for one hour at 37uC, washed in differentiation medium and
stained with goat anti-mouse Alexa 568 (Molecular Probes) for one
hour at 37uC. Cells were then washed in differentiation medium,
fixed with 2% PFA for ten minutes at room temperature, washed
in PBS and permeabilized in 0.3% Triton X-100 for five minutes
at room temperature. Nuclei were counterstained with 49,6-
diamidino-2-phenylindole (DAPI) (1 mg/mL). For FISH, cells were
post-fixed with 4% formaldehyde, treated with 1 mg/mL pepsin,
dehydrated in increasing series of ethanol and air-dried. Cells were
denatured for three minutes at 80uC in hybridization mixture
(70% formamide, 0.5 mg/mL of Cy-3–conjugated PNA probe
specific to human a-satellite sequences (CTCCAAATATC-
CACTTGC), 0.5 mg/mL of Cy-5–conjugated PNA probe specific
to mouse major satellite (GAAGGACCTGGAATATGG) and
0.25% (w/v) blocking reagent (DuPont) in 10 mM Tris (pH 7)).
Hybridization was performed at room temperature for one hour
and slides were then washed with 70% formamide/10 mM Tris
(pH 7.2; twice for fifteen minutes each) and with 0.05 M Tris/
0.15 M NaCl (pH 7.2) containing 0.05% Tween-20 (three times
for five minutes each). Slides were dehydrated, air dried and
counterstained with DAPI (0.2 mg/mL), and mounted in antifad-
ing solution (DABCO).
Lentiviral Vectors
The transfer vector, pLV-HIG, was constructed by inserting the
Ha7 cDNA contained in pHa7, downstream of the EF1a
promoter in the third generation lentiviral vector, pCCL.sin.cPP-
T.EF1a.SET7.IRES.GFP.WPRE utilizing BamH1. The transfer
vector, pLV-FIY, was constructed by first inserting the measles
fusion protein cDNA contained in pCGF, downstream of the
EF1a promoter in the same third generation lentiviral vector
described above, utilizing Xma1 and Xba1. The EYFP cDNA
contained in pEYFP (Clontech) was then cloned downstream of
the IRES utilizing Nco1 and BsrG1.
Lentiviruses were produced by cotransfecting 293T cells with
the appropriate transfer vector as well as with the packaging
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Supernatant was harvested thirty-six to sixty hours later, filtered
through a 0.45 mm filter (Pall) and transferred to subconfluent
cultures of MRC-5 fibroblasts or p53
2/2 C57BL/6 mouse
embryonic fibroblasts in the presence of 5 mg/mL polybrene.
Forty-eight hours after infection, cells were sorted (Becton-
Dickinson FACSVantage) based on expression of YFP and/or
GFP.
Quantitative real-time gene expression analysis
Heterokaryons were generated as described above. Following fusion,
RNA was harvested daily (RNeasy, Qiagen) from a single well for each
treatment condition for a total of eight days. Purified RNA was treated
with DNAse (Fermentas) and cDNA was then produced utilizing
Superscript II (Invitrogen) and random hexamer primers (Invitrogen).
qPCR reactions were set up with Maxima SYBR Green/ROX qPCR
Master Mix (Fermentas) and the following primers pairs hMyoDF: 59-
CACTCCGGTCCCAAATGTAG-39 and hMyoDR: 59-GGTA-
TAAACGTACAAATTCCCTGTA-39.h M y o g e n i n F :5 9-CAGC-
GAATGCAGCTCTCAC-39 and hMyogeninR: 59-CAGAAG-
TAGTGGCATCTGTGG-39. b-actinF: 59-TTTGAGACCTTCAA
CACCCCAGCC-39 and b-actinR: 59-AATGTCACGCACGATT
TCCCGC-39. Gene expression was quantified using a 7900HT Fast
Real-Time PCR System and the 7000 SDS absolute quantification
software (Applied Biosystems).
Chromatin Immunoprecipitation
Heterokaryons were generated as described above. At daily
intervals following fusion, cells were fixed in culture medium
containing 1% formaldehyde for ten minutes at room tempera-
ture. Cross-linking was stopped by addition of glycine to a final
concentration of 0.125 M and incubation for five minutes at room
temperature. Cells were washed twice with ice cold PBS and
harvested by scraping. Pellets were resuspended in 200 mL of lysis
buffer (1% SDS, 50 mM Tris-HCl pH 8.0, 10 mM EDTA,
containing protease inhibitors (Roche)) and frozen at 280uC.
Following collection of all samples, lysates were thawed and
sonicated for 25 cycles (20 s ON (high power), 30 s off) using a
Bioruptor300 (Diagenode). Samples were then diluted 10-fold in
dilution buffer (0.01%SDS, 20 mM Tris-HCl pH 8.0, 167 mM
NaCl, 1.2 mM EDTA, 1.1% Triton X-100) containing protease
inhibitors and were subsequently precleared by incubation with
Protein-A beads (Millipore) for 2 hours at 4uC. Ten percent of
each lysate was then removed to serve as input samples. The
remaining volume was split in half and incubated with either anti-
acetyl-histone H3 (Millipore) or normal rabbit IgG (Millipore)
overnight at 4uC. Protein-A beads were then added and samples
were incubated for 4 hours at 4uC. Antibody-bead complexes
were pelleted at 800xg and washed once in TSE I (0.1%SDS,
2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1%
Triton X-100), once in TSE II (0.1%SDS, 2 mM EDTA, 20 mM
Tris-HCl pH 8.0, 500 mM NaCl, 1% Triton X-100), once in TSE
III (0.25 M LiCl, 1% Deoxycholate, 10 mM Tris-HCl pH 8.0,
1 mM EDTA, 1% NP40) and twice in TE. Samples were
resuspended in elution buffer (1%SDS, 0.1 M NaHCO3) and
incubated for fifteen minutes at room temperature followed by
centrifugation at 800xg to pellet the beads. Supernatants were
transferred to new tubes and NaCl was added to all samples,
including input fractions, to a final concentration of 0.3 M. All
samples were then incubated overnight at 65uC to reverse
crosslinks. DNA was purified using a QIAquick column (Qiagen)
and PCR was performed using primers specific for the human
MyoD locus: hMyoDCHIP1F: 59-CCTGGGCTCCGGGGCGT
TTAG-39 and hMyoDCHIP2R: 59-GCGCGGCACGGTCCTG
GCTT-39. All data was quantified using a 7900HT Fast Real-
Time PCR System and the 7000 SDS absolute quantification
software (Applied Biosystems).
In vivo fusion assay
MEF Ha7/F and MEF Ha7 cells were maintained in DMEM
supplemented with 10% fetal bovine serum and 30 mM b-
mercaptoethanol. Prior to transplantation, cells were trypsinized,
resuspended in PBS and counted. 1610
5 cells from each
population were then intramuscularly injected into 7-week-old
male C57BL/6 recipients utilizing a 26-gauge needle. In the
damage model, cells were co-injected with 10 mL of notexin (1 mg/
mL) (Latoxan). Muscle tissue was then allowed to heal for one
week prior to analysis. As a positive control for the detection of
GFP-positive cells in other organs, 1610
7 whole bone marrow
cells from a GFP-positive mouse (C57BL/6; GFP/CD45.2) were
injected intravenously into wild type mice and these recipients
were harvested three hours later. For analysis, mice were first
terminally anesthetized with avertin, then perfused with PBS
containing 10 mM EDTA and finally perfused with 4% PFA in
PBS. All lower leg muscles as well as the spleen, lung and liver
were then removed from recipients and post-fixed in 4% PFA
overnight prior to overnight cryoprotection in 20% sucrose. All
tissues were then embedded (OCT, Sakura) and cut into 20 mm
(muscle) 10 mm (lung) or 5 mm (spleen and liver) sections (Leica
CM3050S). Muscle sections were stained with rabbit anti-mouse
laminin (Abcam) overnight at 4uC, followed by a one hour
incubation with goat anti-rabbit Alexa 568 (Molecular Probes) at
room temperature. Stained muscle tissues were analyzed by
confocal microscopy using a Nikon C1 laser scanning confocal
microscope and images are presented as maximum intensity
projections of Z stacks of individual optical sections. For analysis of
the spleen, lung and liver, at least 25 sections of each tissue were
examined from each recipient (n=6).
Supporting Information
Figure S1 Reprogramming of human NCAM expression
following Ha7-mediated fusion in vitro. (A) Human NCAM
was expressed by the majority of heterokaryons eight days after
Ha7-mediated fusion of MRC-5 cells and differentiating C2C12
myoblasts. (B,C) Negative controls demonstrating the lack of
human NCAM expression in isolated MRC-5 cells (B) and
differentiated C2C12 cells (C). (D) NCAM-positive heterokaryon
at eight days post-fusion. Scale bar, 50 mm.
(PDF)
Figure S2 Absence of MEFHa7/F cells in the spleen, lung
or liver of transplanted mice. (A,C,E) Positive control
demonstrating GFP-positive cells in the spleen (A), lung (C) and
liver (E) of a wild type recipient following short term homing of
transplanted GFP-positive bone marrow. (B,D,F) No GFP-
positive cells were observed in the spleen (B), lung (D) or liver
(F) of wild type recipients following transplantation of MEFHa7/F
cells. Scale bar, 100 mm.
(PDF)
Table S1 Percentage of myotubes expressing GFP
following Ha7-mediated fusion, PEG-mediated fusion
or co-culture of 293TGFP cells and differentiating C2C12
myotubes.
(PDF)
Table S2 Fold increase in the number of GFP-positive
myotubes observed following Ha7-mediated fusion of
293TGFP cells and differentiating C212 myotubes as
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mediated fusion.
(PDF)
Table S3 Fold increase in human MyoD and myogenin
transcript levels detected following Ha7-mediated fu-
sion of MRC-5 cells and differentiating C2C12 myotubes
as compared to the levels detected following PEG-
mediated fusion. (Ha7 signal/PEG signal).
(PDF)
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